SITES PATIENTS

Krystyna Kowalczyk Named CEO of Moffitt Cancer Center’s Immunotherapy Contract Research Organization

Krystyna Kowalczyk Named CEO of Moffitt Cancer Center’s Immunotherapy Contract Research Organization
TAMPA, Fla. — Krystyna Kowalczyk has joined Moffitt Cancer Center as the chief executive officer of the institution’s new contract research organization (CRO) with a focus on immunotherapy. The wholly owned, for profit subsidiary, first announced in October 2019, will offer end-to-end services for pharmaceutical and biotech companies looking to advance their immuno-oncology product or device.

Read more

The Latest News & Events

Press Releases

NEXT Oncology and OncoBay Clinical Collaborate on Six Phase 1 Clinical Trials

Read more

Blog

FDA Black Box Warning for CAR-T cell therapies highlights the necessity for long-term monitoring

Read more

Blog

The Revolution in Medicine: Marker-Driven Targeted Drug Development

Read more
SEE ALL NEWS & EVENTS

Take Advantage of OncoBay’s Innovative Approach

CONTACT ONCOBAY CLINICAL

Submit a Request for Proposal

Submit Proposal

OncoBay is now Kapadi

 

Once three entities – OncoBay Clinical, Clinscience, and Exom Group s.r.l – now we stand as one, bringing forth a symphony of expertise and seamless operations. To celebrate our unity, we re-brand under the banner of Kapadi, and embark on a new chapter of exceptional service in oncology clinical research.

Kapadi is not just a name; it's a testament to our fusion. It signifies the our standing as a global CRO powerhouse committed to accelerating groundbreaking cancer therapies that uplift patients worldwide. From conceptualizing studies, navigating regulations, and analyzing data, we provide a comprehensive array of services designed to empower your oncology clinical trials.

 

Visit Kapadi.com

 

This pop-up will auto-close in 10 seconds.

This will close in 5 seconds